Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 14 | 2025 | 712 | 4.220 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 173 | 2.640 |
Why?
|
| Vaccination | 13 | 2024 | 688 | 2.010 |
Why?
|
| Analgesics, Opioid | 5 | 2025 | 245 | 1.850 |
Why?
|
| Wounds, Gunshot | 2 | 2024 | 18 | 1.710 |
Why?
|
| Cancer Survivors | 2 | 2025 | 101 | 1.680 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2023 | 18 | 1.670 |
Why?
|
| Humans | 58 | 2025 | 17314 | 1.550 |
Why?
|
| Adult | 32 | 2025 | 7500 | 1.520 |
Why?
|
| California | 24 | 2025 | 2311 | 1.500 |
Why?
|
| Male | 43 | 2025 | 9804 | 1.500 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 159 | 1.390 |
Why?
|
| Female | 44 | 2025 | 12396 | 1.310 |
Why?
|
| Vaccines | 6 | 2022 | 220 | 1.230 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2017 | 59 | 1.230 |
Why?
|
| Adolescent | 23 | 2025 | 3538 | 1.220 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2022 | 535 | 1.220 |
Why?
|
| Middle Aged | 28 | 2025 | 7836 | 1.210 |
Why?
|
| Electronic Health Records | 5 | 2024 | 704 | 1.200 |
Why?
|
| Retrospective Studies | 19 | 2025 | 2415 | 1.130 |
Why?
|
| Managed Care Programs | 6 | 2017 | 300 | 1.080 |
Why?
|
| Firearms | 2 | 2024 | 31 | 1.040 |
Why?
|
| Papillomavirus Vaccines | 6 | 2022 | 114 | 0.990 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 5 | 2017 | 32 | 0.970 |
Why?
|
| Young Adult | 18 | 2025 | 2465 | 0.970 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 31 | 0.920 |
Why?
|
| Neoplasms | 3 | 2025 | 446 | 0.900 |
Why?
|
| Cohort Studies | 18 | 2025 | 2514 | 0.890 |
Why?
|
| Aged | 18 | 2025 | 6084 | 0.890 |
Why?
|
| Sexual Behavior | 1 | 2025 | 128 | 0.880 |
Why?
|
| Machine Learning | 1 | 2024 | 53 | 0.860 |
Why?
|
| Community Health Centers | 1 | 2024 | 64 | 0.860 |
Why?
|
| Chronic Pain | 2 | 2022 | 127 | 0.840 |
Why?
|
| Vaccination Coverage | 1 | 2024 | 52 | 0.830 |
Why?
|
| Chickenpox Vaccine | 3 | 2015 | 91 | 0.810 |
Why?
|
| Papillomavirus Infections | 6 | 2022 | 142 | 0.800 |
Why?
|
| Health Behavior | 1 | 2025 | 346 | 0.800 |
Why?
|
| Fractures, Bone | 1 | 2023 | 92 | 0.800 |
Why?
|
| Immunization, Secondary | 3 | 2016 | 59 | 0.760 |
Why?
|
| Chickenpox | 2 | 2012 | 35 | 0.730 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 165 | 0.720 |
Why?
|
| Herpes Zoster | 4 | 2016 | 82 | 0.700 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 96 | 0.690 |
Why?
|
| United States | 14 | 2024 | 3866 | 0.630 |
Why?
|
| Hypertension | 1 | 2023 | 469 | 0.610 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2019 | 93 | 0.600 |
Why?
|
| Incidence | 5 | 2025 | 1266 | 0.570 |
Why?
|
| Electronics, Medical | 1 | 2018 | 3 | 0.570 |
Why?
|
| Risk Factors | 9 | 2025 | 3258 | 0.550 |
Why?
|
| Buprenorphine | 3 | 2025 | 48 | 0.550 |
Why?
|
| Medicare Part D | 1 | 2017 | 15 | 0.540 |
Why?
|
| Hospitalization | 5 | 2025 | 804 | 0.540 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 969 | 0.540 |
Why?
|
| Cost Sharing | 1 | 2017 | 28 | 0.540 |
Why?
|
| Coinfection | 2 | 2019 | 31 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 109 | 0.510 |
Why?
|
| Age Factors | 5 | 2025 | 878 | 0.470 |
Why?
|
| Primary Health Care | 4 | 2021 | 726 | 0.460 |
Why?
|
| Influenza Vaccines | 4 | 2019 | 292 | 0.450 |
Why?
|
| Viral Load | 3 | 2021 | 136 | 0.450 |
Why?
|
| Child | 13 | 2022 | 2403 | 0.450 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 381 | 0.440 |
Why?
|
| Tenofovir | 2 | 2023 | 18 | 0.420 |
Why?
|
| Hepatitis B | 1 | 2014 | 45 | 0.420 |
Why?
|
| Preventive Medicine | 1 | 2013 | 22 | 0.410 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 54 | 0.400 |
Why?
|
| Drug Utilization | 1 | 2013 | 121 | 0.400 |
Why?
|
| Mothers | 1 | 2013 | 103 | 0.380 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 3 | 0.380 |
Why?
|
| Herpes Simplex | 1 | 2012 | 7 | 0.380 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 44 | 0.380 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 68 | 0.370 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2022 | 181 | 0.360 |
Why?
|
| Databases, Factual | 1 | 2012 | 304 | 0.360 |
Why?
|
| Abortion, Spontaneous | 3 | 2021 | 49 | 0.360 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 112 | 0.350 |
Why?
|
| Risk Assessment | 4 | 2024 | 1076 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 302 | 0.340 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1925 | 0.330 |
Why?
|
| Seizures, Febrile | 3 | 2015 | 42 | 0.330 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 45 | 0.310 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 72 | 0.310 |
Why?
|
| Meningococcal Vaccines | 3 | 2022 | 39 | 0.300 |
Why?
|
| Child, Preschool | 7 | 2017 | 1380 | 0.300 |
Why?
|
| Proportional Hazards Models | 4 | 2025 | 701 | 0.280 |
Why?
|
| Hepatitis C | 2 | 2021 | 65 | 0.280 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 151 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 9 | 0.240 |
Why?
|
| Survivorship | 1 | 2025 | 12 | 0.240 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 18 | 0.230 |
Why?
|
| Benzodiazepines | 1 | 2025 | 28 | 0.230 |
Why?
|
| Self-Injurious Behavior | 1 | 2025 | 44 | 0.220 |
Why?
|
| Comorbidity | 3 | 2021 | 560 | 0.220 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 44 | 0.220 |
Why?
|
| Radiculopathy | 1 | 2023 | 5 | 0.210 |
Why?
|
| Fumarates | 1 | 2023 | 4 | 0.210 |
Why?
|
| Self Report | 1 | 2025 | 257 | 0.210 |
Why?
|
| Adenine | 1 | 2023 | 8 | 0.210 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 24 | 0.210 |
Why?
|
| Health Status | 1 | 2025 | 293 | 0.210 |
Why?
|
| Age Distribution | 1 | 2023 | 239 | 0.200 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2025 | 640 | 0.200 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 146 | 0.190 |
Why?
|
| Infant | 6 | 2018 | 1161 | 0.190 |
Why?
|
| Immunization Schedule | 2 | 2022 | 124 | 0.190 |
Why?
|
| Premature Birth | 2 | 2021 | 132 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 2 | 2015 | 151 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1280 | 0.180 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 146 | 0.180 |
Why?
|
| Vaccines, Combined | 2 | 2019 | 80 | 0.180 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2022 | 88 | 0.180 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 92 | 0.170 |
Why?
|
| Algorithms | 1 | 2022 | 223 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 390 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2020 | 34 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 24 | 0.160 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 3 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 30 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 13 | 0.160 |
Why?
|
| Logistic Models | 3 | 2025 | 879 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 31 | 0.150 |
Why?
|
| Risk | 2 | 2018 | 496 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 100 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2025 | 277 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 15 | 0.140 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 10 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 535 | 0.130 |
Why?
|
| Preconception Care | 1 | 2017 | 40 | 0.130 |
Why?
|
| Meningitis, Meningococcal | 1 | 2017 | 7 | 0.130 |
Why?
|
| Heart Failure | 1 | 2022 | 401 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 27 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2017 | 61 | 0.130 |
Why?
|
| Stroke | 1 | 2019 | 309 | 0.130 |
Why?
|
| Time Factors | 3 | 2016 | 1039 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.130 |
Why?
|
| Policy Making | 1 | 2016 | 13 | 0.120 |
Why?
|
| Prenatal Care | 1 | 2017 | 127 | 0.120 |
Why?
|
| Alcoholism | 1 | 2019 | 337 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 2015 | 1 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2015 | 85 | 0.120 |
Why?
|
| Ribavirin | 1 | 2015 | 8 | 0.120 |
Why?
|
| Sex Factors | 2 | 2015 | 603 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 672 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2015 | 52 | 0.120 |
Why?
|
| African Americans | 2 | 2017 | 439 | 0.110 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.110 |
Why?
|
| Ethnic Groups | 3 | 2014 | 451 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2015 | 99 | 0.110 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2015 | 62 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 252 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 7 | 0.110 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.110 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 15 | 0.110 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 25 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 58 | 0.110 |
Why?
|
| Gonorrhea | 1 | 2014 | 19 | 0.110 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 23 | 0.110 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 407 | 0.100 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 23 | 0.100 |
Why?
|
| Quality Control | 1 | 2012 | 41 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 102 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2016 | 282 | 0.100 |
Why?
|
| Men's Health | 1 | 2012 | 20 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2012 | 17 | 0.090 |
Why?
|
| Vascular Calcification | 1 | 2012 | 8 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2025 | 1160 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2021 | 805 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 342 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 116 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 203 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1098 | 0.080 |
Why?
|
| Smoking | 1 | 2013 | 429 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 21 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 674 | 0.080 |
Why?
|
| Pregnancy | 3 | 2021 | 1463 | 0.080 |
Why?
|
| Stillbirth | 2 | 2021 | 29 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 664 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 1282 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 840 | 0.070 |
Why?
|
| Seasons | 2 | 2019 | 113 | 0.070 |
Why?
|
| Cause of Death | 2 | 2018 | 176 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2025 | 338 | 0.050 |
Why?
|
| Headache | 1 | 2023 | 14 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 312 | 0.050 |
Why?
|
| Back Pain | 1 | 2023 | 32 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 29 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1151 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 101 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Naltrexone | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 8 | 0.040 |
Why?
|
| Appendicitis | 1 | 2019 | 14 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 25 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 43 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 50 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 170 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 192 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 23 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 397 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2017 | 59 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2017 | 27 | 0.030 |
Why?
|
| Bell Palsy | 1 | 2017 | 14 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2020 | 274 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 13 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 158 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 54 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 31 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 57 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2015 | 65 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 252 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 107 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 223 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 5 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 96 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2017 | 375 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 476 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 18 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 74 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 270 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 112 | 0.030 |
Why?
|
| Minority Groups | 1 | 2013 | 104 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 384 | 0.020 |
Why?
|
| Calcitriol | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hypocalcemia | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hyperphosphatemia | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2010 | 2 | 0.020 |
Why?
|
| Ergocalciferols | 1 | 2010 | 3 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hypophosphatemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2010 | 12 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 8 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 13 | 0.020 |
Why?
|
| Minerals | 1 | 2010 | 8 | 0.020 |
Why?
|
| Calcinosis | 1 | 2010 | 35 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2010 | 74 | 0.020 |
Why?
|
| Vitamin D | 1 | 2010 | 73 | 0.020 |
Why?
|
Concepts
(244)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(48)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->